1Conti M, Jin SL. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol, 1999, 63(1):1-38.
2Landells LJ, Szilagy CM, Jones NA, et al. Identification and quantification of phosphodiesterase 4 sybtypes in CD4 and CD8lymphocytes from healthy and asthematic subjectsl. Br J Pharmacol, 2001,133 (5) :722-729.
3Wang P,Wu P,Ohleth KM,et al. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neut rophils. Mol Pharmacol, 1999,56 ( 1 ): 170-174.
4Macdonald D, Perrier H, Liu S, et al. Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-( 3-azidophenyl )-6-[( 4-iodo-1-H-1-imidazolyl) methyl] quinoline (APIIMQ). J Med Chem, 2000,43(21) :3820-3823.
5Kerstjens AM, Timens W. Phosphodiesterase 4 inhibitors antiinflammatory therapy for chronic obstructive pulmonary disease at last?. Am J Respir Crit Care Med,2003,168(8) :914-915.
6Gamble E, Grootendorst DC, Brightling CE, et al.Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med,2003,168(8) :976-982.
7Peter J, Barnes DS. Chronic obstructive pulmonary disease. N Eng J Med,2000,343(26) :269-280.
8Carol A,Pettersen MS, Kenneth B, et al. Airways inflammation and COPD: epithelial-neutrophil interactions. Chest, 2002, 121(5): 142s-150s.
9Tetley TD. Macrophages and the pathogenesis of COPD. Chest,2002,121 (5): 156s-159s.
10MacNee W. Oxidants/antioxidants and COPD. Chest, 2000, 117(5) : 303s-317s.
3Donald P, Tashkin Robert P, Murray, et al. Smoking cessation in chronic obstructive pulmonary disease [ J ]. Respiratory Medicine, 2009,103 (7) :963-974.
4Stoloff SW. Chronic obstructive pulmonary disease megatrlals : taking the resnh into the office practice[J]. Am j Med Sci,2010,342(2) : 160-167.
5Celli BR, Cote CG, Lareau SC, et al. Predictors of Survival in COPD : more than just the FEV1 [J]. Respiratory Medicine,2008,6(2) :27- 35.
6Miravitlles M, Anzueto A. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies [ J ]. Internationl Journal Chro Obstrct Pulmon Dis,2009 (4) : 185 -201.
7Calverley PM,Anderson JA,Celli B,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease[ J ]. The New England Journal of Medicine,2007,356 (8) :775-788.
8Bogdan MA, Aizawa H, Fukuchi Y,et al. Efficacy and safety of in- haled forrnoterol 4.5 and 9p.g twice daily in Japanese and European COPD patients: phase study results [J]. BMC Pulmonary Medi- cine,2011,11 (15) :1-9.
9Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacatote- rol 150mg once-daily in COPD : a double-blind, randomized, 12-week study[ J]. BMC Pulmonary Medicine,2010 ,8 (10) :11.
10Vogelmeier Claus, Ramos-Barbon David, Jack Damon, et al. Inda- caterol provides 24-hour bronchodilation in COPD: a placebo-con- trolled blinded comparison with tiotropium [ J ]. Respiratory Re- search ,2010,11 ( 1 ) : 135.
